首页> 外文期刊>Veterinary Microbiology >Oral co-administration of live attenuated Salmonella enterica serovar Typhimurium expressing chicken interferon-alpha and interleukin-18 enhances the alleviation of clinical signs caused by respiratory infection with avian influenza virus H9N2
【24h】

Oral co-administration of live attenuated Salmonella enterica serovar Typhimurium expressing chicken interferon-alpha and interleukin-18 enhances the alleviation of clinical signs caused by respiratory infection with avian influenza virus H9N2

机译:口服共同表达减毒活肠沙门氏菌血清鼠伤寒沙门氏菌表达鸡干扰素-α和白介素-18增强了禽流感病毒H9N2呼吸道感染引起的临床症状的缓解

获取原文
获取原文并翻译 | 示例
           

摘要

The combined use of cytokines has shown synergistic and/or additive effects in controlling several viral infections of livestock animals. However, little is known concerning the practical use of chicken cytokine combinations to control avian diseases. Here, we investigated the antiviral efficacy of oral co-administration of chicken interferon-alpha (chIFN-alpha) and chicken interleukin-18 (chIL-18) using attenuated Salmonella enterica serovar Typhimurium in chickens infected with avian influenza virus (AIV) H9N2. Our results demonstrate that oral co-administration of S. enterica serovar Typhimurium expressing chIFN-alpha and chIL-18 produced a greater alleviation of clinical signs caused by respiratory infection with AIV H9N2 in chickens, when compared to administration of S. enterica serovar Typhimurium expressing either chIFN-alpha or chIL-18 alone. Mortality, clinical symptom severity, and feed and water intake were used to access treatment effectiveness. This enhancement of antiviral immunity was further confirmed by evidence of reduced rectal shedding and decreased replication of AIV H9N2 in several different tissues of challenged chickens including trachea, lung, cecal tonsil, and brain. Furthermore, oral co-administration of chIFN-alpha and chIL-18 more efficiently modulated the immune responses of chickens against AIV H9N2 by enhancing both humoral and Th1-biased cell-mediated immunity, compared to single administration of either construct. Therefore, our results suggest that the combined administration of two chicken cytokines, chIFN-alpha and chIL-18, using attenuated S. enterica serovar Typhimurium as an oral carrier, provides an effective means for controlling respiratory disease caused by AIV H9N2 infection. (C) 2011 Elsevier B.V. All rights reserved.
机译:在控制牲畜的几种病毒感染中,细胞因子的联合使用已显示出协同和/或累加作用。然而,关于将鸡细胞因子组合物用于控制禽类疾病的实际用途知之甚少。在这里,我们研究了使用减毒沙门氏菌血清型鼠伤寒沙门氏菌口服联合给药鸡干扰素-α(chIFN-α)和鸡白细胞介素-18(chIL-18)的抗病毒功效,该鸡感染了禽流感病毒(AIV)H9N2。我们的研究结果表明,与表达肠炎沙门氏菌的鼠伤寒沙门氏菌相比,表达chIFN-α和chIL-18的肠炎沙门氏菌的鼠伤寒沙门氏菌口服联合给药可更大程度减轻鸡用AIV H9N2呼吸道感染引起的临床症状。单独使用chIFN-alpha或chIL-18。死亡率,临床症状严重程度以及饲料和水的摄入量可用于获得治疗效果。抗病毒免疫力的这种增强进一步通过减少受攻击鸡的几种不同组织(包括气管,肺,盲肠扁桃体和脑)的直肠脱落和AIV H9N2复制减少的证据进一步证实。此外,与任何一种构建体的单次给药相比,口服chIFN-α和chIL-18的共同给药通过增强体液和偏向Th1的细胞介导的免疫力,更有效地调节了鸡对AIV H9N2的免疫反应。因此,我们的结果表明,使用减毒的肠炎链球菌血清鼠伤寒沙门氏菌作为口服载体,两种鸡细胞因子chIFN-α和chIL-18的联合给药,为控制由AIV H9N2感染引起的呼吸道疾病提供了有效的手段。 (C)2011 Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号